{"id":26061,"date":"2026-02-13T16:46:03","date_gmt":"2026-02-13T14:46:03","guid":{"rendered":"https:\/\/makingpharmaindustry.it\/non-categorizzato\/tendenze-2026-nello-sviluppo-farmaceutico\/"},"modified":"2026-02-17T17:24:22","modified_gmt":"2026-02-17T15:24:22","slug":"tendenze-2026-nello-sviluppo-farmaceutico","status":"publish","type":"post","link":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/tendenze-2026-nello-sviluppo-farmaceutico\/","title":{"rendered":"Pharmaceutical Development Trends for 2026"},"content":{"rendered":"

According to industry analysts, in 2026 the pharmaceutical sector is coming to terms with a hard truth: its core challenge is no longer innovation, but industrialization.<\/p>\n

After a selectively rebounding 2025\u2014marked by a revival in M&A activity and a biotech sector that proved more resilient than during the 2022\u20132023 contraction\u2014the industry is entering a phase of enforced maturity. Pressures have not eased; they have stabilized.<\/p>\n

According to PwC\u2019s US Deals Outlook 2026<\/em><\/a>, the patent cliff between 2026 and 2029 puts between $47 billion and $176 billion in global sales at risk of erosion. In the United States, the Inflation Reduction Act (IRA) is compressing commercial exclusivity windows. China continues to consolidate its position as a global biotech powerhouse. Europe, meanwhile, faces a structural dilemma between regulatory sophistication and industrial competitiveness.<\/p>\n

\n

Global Market Outlook<\/strong><\/h4>\n

$2.6 trillion<\/strong> in projected global pharmaceutical spending by 2030<\/p>\n

Expected CAGR:<\/strong> 5\u20138%
(Source: IQVIA \u2013 Global Use of Medicines 2026 Outlook<\/em>)<\/p>\n

\n

Patent Cliff Exposure<\/strong><\/h4>\n

$47\u2013176 billion<\/strong> in sales at risk between 2026 and 2029
(Source: PwC \u2013 US Deals Outlook 2026<\/em>)<\/p>\n

\n

Blockbuster Dominance<\/strong><\/h4>\n

Approximately 90% of revenues<\/strong> among the top 20 biopharma companies derived from blockbuster or mega-blockbuster products
(Source: BCG \u2013 Biopharma Trends 2026<\/em>)<\/p>\n

\n

AI Adoption Gap<\/strong><\/h4>\n

78% of C-level executives<\/strong> identify AI as a central transformation driver<\/p>\n

Only 22%<\/strong> have successfully scaled AI beyond pilot programs
(Source: ZS \u2013 Pharma Industry Outlook 2026<\/em>)<\/p>\n

\n

U.S. Reshoring Wave<\/strong><\/h4>\n

$350 billion<\/strong> in announced investments in manufacturing capacity through 2030
(Source: BCG \u2013 Reimagining Business Models 2026<\/em>)<\/p>\n

\n

Global Pipeline Shift<\/strong><\/h4>\n

Approximately 30% of the global biotech pipeline<\/strong> originates in China
(Source: Evaluate + BCG 2026 analysis)<\/p>\n<\/blockquote>\n

 <\/p>\n

The return of scalable therapies<\/h2>\n

For more than a decade, the dominant narrative in biopharma centered on extreme personalization: CAR-T therapies, gene therapies, and increasingly narrow molecular niches.<\/p>\n

In 2026, the pendulum begins to swing back.<\/p>\n

According to BCG\u2019s Reimagining Business Models: Biopharma Trends 2026<\/em><\/a>, approximately 90% of revenues among the top 20 biopharma companies will continue to come from blockbusters or mega-blockbusters at least through 2030.<\/p>\n

The strategic focus is shifting toward innovative therapies designed for large patient populations:<\/p>\n